basal cell carcinoma

New and Emerging Therapies for Advanced Non-Melanoma Skin Cancer
Advanced Non-Melanoma Skin CancerAt the 17th Annual ODAC Dermatology, Aesthetic and Surgical Conference held January 17-20 in Orlando, FL, Dr. Desiree Ratner led a discussion on new and emerging therapies for advanced non-melanoma skin cancer. The session covered several treatments for patients including patidegib gel 2% and 4% applied once or twice daily in patients with basal cell carcinoma. Patidegib is a topical hedgehog in …
Advanced Non-Melanoma Skin Cancer
Recurrent Squamous Cell Carcinoma Arising Within a Linear Porokeratosis
SCCJDD authors Amelia M. Abbott-Frey BA, Alexandra J. Coromilas MD, George W. Niedt MD, and Jesse M. Lewin MD report a case of linear porokeratosis with recurrent malignant degeneration to squamous cell carcinoma (SCC) recurring six years after excision of initial SCC. Case Report A 79-year-old woman with a history of hypertension and hypothyroidism presented with a friable tumor within a lesion o …
SCC
Methacrylate Polymer Powder Dressing for a Nasal Surgical Defect
Methacrylate Polymer Powder Dressing for a Nasal Surgical DefectThe fusion of technology and medicine has led to the advent of advanced wound healing techniques that may be adapted to the management of surgical defects. Shortened duration of healing and ease-of-use are two potential benefits under investigation. Here, Matthew J. Lin MD, Danielle P. Dubin BA, Aaron S. Farberg MD, Hooman Khorasani MD, David A. Kriegel MD describe a 65-year-old male with a nasal …
Methacrylate Polymer Powder Dressing for a Nasal Surgical Defect
JDD March Issue Highlights and Editor Picks
JDD logoBelow are the issue highlights and Editor Picks for the March issue of JDD! Papp and Lebwohl review clinical data on the use of biologics in moderate-to-severe psoriasis, identifying which biologics may offer the quickest results in Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.   In Clinical Insights About Onychomycosis and Its Treatment: A Consensus, au …
JDD logo